




4TH ANNUAL

Acute Lymphoblastic Leukemia

Fellows Scholar Program

October 24–25, 2026

Chicago Marriott O'Hare
Rosemont, IL



Presented by Creative Educational Concepts and supported by an independent educational grant from Jazz Pharmaceuticals.

OVERVIEW

Oncology fellows and pediatric oncology fellows who are nominated to attend the Acute Lymphoblastic Leukemia Fellows Scholar Program (ALLFSP) are selected by their program directors. Ideal candidates for the program are dedicated to enhancing their understanding of acute lymphoblastic leukemia (ALL) across various age groups and to advancing their knowledge of treatment methods. During this multi-day meeting, fellows attend interactive learning sessions with expert faculty and participate in breakout workshops in which they discuss clinical cases with colleagues from across the United States. Each participant is required to prepare and present one brief case study on an ALL-related topic of their choice.

ACTIVITY DESCRIPTION

The ALLFSP is an intensive multi-day course designed for adult and pediatric hematology/oncology fellows to expand their education and understanding of the complex and evolving therapeutic space of ALL. The primary objective for the third installment of this program is to provide fellows with a thorough review of the current management for ALL across diverse patient populations. Additionally, the agenda aims to foster discussions on evaluating and differentiating current treatment options, refining treatment approaches and care plans, the future trajectory of therapy, and the questions that are driving research.

WHO SHOULD ATTEND

Fellows who are nominated to attend the ALLFSP are selected by their program directors. Ideal candidates for the program are at least in their second year of an adult or pediatric hematology/oncology fellowship (exceptions for first-year fellows may be considered on a case-by-case basis) and are committed to furthering their knowledge of the treatment of ALL. During this multi-day meeting, fellows attend interactive learning sessions with expert faculty and participate in breakout workshops in which they discuss clinical cases with colleagues from across the United States. Each registrant is required to prepare and present one brief case study on an ALL-related topic of their choice. Attendees of the 2026 ALLFSP will receive a detailed electronic handout and other resources related to the treatment of ALL.



REGISTRATION

Thank you for your interest in the 4th Annual Acute Lymphoblastic Leukemia Fellows Scholar Program. Program directors are asked to nominate and register one pediatric or adult hematology/oncology fellow from their program to receive the scholarship and attend the entire ALLFSP. If you have questions about this program, please contact **Ashley Lilly**, Account Director, at lillya@ceconcepts.com.

Please note: The program starts on Saturday, October 24, and ends Sunday, October 25. The nominated pediatric or adult hematology/oncology fellow will need to complete the online registration at ceconcepts.com/allfsp.

IMPORTANT DATES

FRIDAY
SEPT
25
Registration
Deadline

FRIDAY
OCT
16
Case Studies
Deadline

TRAVEL

Each participant will receive a \$450 travel scholarship on-site at ALLFSP.

- Attendees are responsible for their airfare to and from Chicago.
- Attendees will reserve a hotel room via a secure hotel website once registration is confirmed.

CASE STUDY

All registrants are required to present an ALL-related clinical case during their assigned case study breakout session. All case study presentations must be submitted in advance in PowerPoint format. The presentation should include no more than 6–8 slides, with the expectation of approximately 10 minutes for both presentation and discussion. Case study submission requirements will be emailed to fellows following registration.



The ALL Fellows Scholar Program provided a great opportunity to network with fellows across institutions, with the unique feature of bringing together trainees across both adult and pediatric oncology, which outside of this venue has been rare in my training. It was interesting to learn about differences in ALL management across institutions and between pediatric and adult populations, and to form connections with fellows at varying stages of training who I am sure will be a valuable resource going forward in discussing difficult cases, and exchanging advice as we continue to navigate careers in malignant hematology.

🔧 ACTIVITY CHAIR



Emily K. Curran
MD
Assistant Professor,
Division of Hematology/Oncology
Medical Director, UCCC Clinical Trials Office
University of Cincinnati Cancer Center
Cincinnati, OH

🔧 INVITED FACULTY



Adam Duvall
MD, MPH
Associate Professor of Medicine and Pediatrics
HIAYA Program Co-Director
University of Utah
Huntsman Cancer Institute
Salt Lake City, UT



Marlise R. Luskin
MD, MSCE
Senior Physician
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, MA



Luke Maese
DO
Associate Professor of Pediatrics
University of Utah Huntsman Cancer Institute
Pediatric Hematology/Oncology
Primary Children's Hospital
Salt Lake City, UT



Julie Wolfson
MD, MSHS
Associate Professor, Pediatric Hematology-Oncology
Institute for Cancer Outcomes and Survivorship
Director, Adolescent and Young Adult
Oncology & Oncofertility Program
University of Alabama–Birmingham
Birmingham, AL

🔧 TENTATIVE AGENDA

SATURDAY, OCTOBER 24, 2026	
12:30 PM–1:30 PM	Registration
1:30 PM–2:00 PM	Introductions from Activity Chair
2:00 PM–6:00 PM	Educational Sessions*
6:00 PM–7:00 PM	Meet the Faculty Dinner

SUNDAY, OCTOBER 25, 2026	
7:30 AM–8:00 AM	Buffet Breakfast
8:00 AM–10:00 AM	Educational Sessions*
10:00 AM–12:00 PM	Small Group Case Presentations
12:00 PM–12:30 PM	Buffet Lunch
12:30 PM–2:30 PM	Educational Sessions*
2:30 PM–3:00 PM	Wrap-up/Final Discussion
3:00 PM	Departures

**Session is eligible for AMA PRA Category 1 Credit*

LEARNING OBJECTIVES

1. Select age-appropriate, risk-adapted frontline regimens for pediatric, AYA, and adults with ALL.
2. Select appropriate therapies for relapsed/refractory (R/R) ALL based on prior treatment exposure and disease risk.
3. Integrate strategies to mitigate and manage acute and chronic toxicities in patients with Ph+ ALL receiving tyrosine kinase inhibitors (TKIs) and immunotherapies.
4. Apply evidence-informed approaches to the management of lineage switch between ALL and acute myeloid leukemia (AML).
5. Align treatment recommendations with patient values and goals in survivorship care for adolescents and young adults with ALL.
6. Incorporate strategies to improve care coordination for patients with ALL in community oncology settings.

🔧 ACCREDITATION



In support of improving patient care, Creative Educational Concepts, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

ACCME (Physician): CEC designates this live educational activity for a maximum of 7 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.